Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine |
| |
Authors: | Partidos Charalambos D Paykel Joanna Weger James Borland Erin M Powers Ann M Seymour Robert Weaver Scott C Stinchcomb Dan T Osorio Jorge E |
| |
Institution: | Inviragen, Inc, Madison, 6502 Odana Rd, Madison, WI 53719, USA. hpartidos@inviragen.com |
| |
Abstract: | Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease. |
| |
Keywords: | Chikungunya virus (CHIKV) O‘nyong–nyong virus (ONNV) A129 mice Interferon (IFN) Maternal–fetal immunity |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|